Show simple item record

dc.contributor.authorMytton, O T*
dc.contributor.authorAshley, E A*
dc.contributor.authorPeto, L*
dc.contributor.authorPrice, R N*
dc.contributor.authorLa, Y*
dc.contributor.authorHae, R*
dc.contributor.authorSinghasivanon, P*
dc.contributor.authorWhite, N J*
dc.contributor.authorNosten, F*
dc.date.accessioned2009-03-05T15:50:30Z
dc.date.available2009-03-05T15:50:30Z
dc.date.issued2007-09
dc.date.submitted2009-03-04
dc.identifier.citationElectrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. 2007, 77 (3):447-50 Am. J. Trop. Med. Hyg.en
dc.identifier.issn0002-9637
dc.identifier.pmid17827358
dc.identifier.urihttp://hdl.handle.net/10144/52376
dc.description.abstractDihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.
dc.description.sponsorshipEpicentreen
dc.language.isoenen
dc.publisherAmerican Society of Tropical Medicine and Hygieneen
dc.relation.urlhttp://www.ajtmh.orgen
dc.rightsArchived on this site with the kind permission of the American Society of Tropical Medicine and Hygiene, http://www.astmh.orgen
dc.subject.meshArrhythmias, Cardiacen
dc.subject.meshArtemisininsen
dc.subject.meshElectrocardiographyen
dc.subject.meshHumansen
dc.subject.meshMalaria, Falciparumen
dc.subject.meshSesquiterpenesen
dc.titleElectrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria.en
dc.typeArticleen
dc.contributor.departmentShoklo Malaria Research Unit, Mae Sot, Thailand.en
dc.identifier.journalThe American Journal of Tropical Medicine and Hygieneen
refterms.dateFOA2019-03-04T12:17:39Z
html.description.abstractDihydroartemisinin-piperaquine (DP) could become a leading fixed combination malaria treatment worldwide. Although there is accumulating evidence of efficacy and safety from clinical trials, data on cardiotoxicity are limited. In two randomized controlled trials in Thailand, 56 patients had ECGs performed before treatment, 4 hours after the first dose, and 4 hours after the last dose. The mean (95% CI) changes in QTc interval (Bazett's correction) were 2 (-6 to 9) ms and 14 (7 to 21) ms, respectively. These small changes on the third day of treatment are similar to those observed elsewhere in the convalescent phase following antimalarial treatment with drugs known to have no cardiac effects and are therefore likely to result from recovery from acute malaria and not the treatment given. At therapeutic doses, DP does not have clinically significant effects on the electrocardiogram.


Files in this item

Thumbnail
Name:
408_Mytton_DP_ECG_Safety_AmJTr ...
Size:
62.78Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record